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Serum prolidase activity, total oxidant/antioxidant, and nitric oxide levels in 
patients with esophageal squamous cell carcinoma
Özofagusun skuamöz hücreli karsinomu olan hastalarda serum prolidaz aktivitesi, 
total oksidan/antioksidan ve nitrik oksit düzeyleri
Fuat Sayır1, Abidin Şehitoğulları2, Halit Demir3, Mehmet Aslan4, Ufuk Çobanoğlu1, Cahit Bilgin5
ÖZ
Amaç: Bu çalışmada özofagusun skuamöz hücreli karsinomu 
olan hastalarda prolidaz aktivitesi, nitrik oksit düzeyleri ve 
oksidatif durum değerlendirildi.
Ça­lış­ma­ pla­nı:­ Çalışmaya özofagusun skuamöz hücreli 
karsinomu olan 30 hasta (11 erkek, 19 kadın; ort. yaş 61±3 yıl; 
dağılım, 28-77 yıl) ve 30 sağlıklı kontrol (10 erkek, 20 kadın; 
ort. yaş 58±5 yıl; dağılım, 31-73 yıl) dahil edildi. Serum prolidaz 
aktivitesi, total antioksidan kapasitesi, total oksidan durumu 
ve nitrik oksit düzeyleri ölçüldü. Ayrıca, oksidatif stres indeksi 
hesaplandı.
Bul gu lar: Hasta grubunda belirgin şekilde artmış serum 
prolidaz aktivitesi, oksidatif stres indeksi değerleri, total 
oksidan durumu ve nitrik oksit düzeyleri saptandı (p<0.05). 
Hasta grubunda daha düşük total antioksidan kapasitesi 
düzeyleri gözlendi (p<0.05).
So­nuç:­Özofagusun skuamöz hücreli karsinomu olan hastalarda 
artmış nitrik oksit düzeyleri ve prolidaz aktivitesi ile artmış 
oksidan durumu bulundu. Artmış prolidaz aktivitesi ve 
nitrik oksit düzeyleri ile antioksidan mekanizma bozukluğu, 
özofagusun skuamöz hücreli karsinomunun etyopatogenezinde 
önemli rol oynayabilir.
Anah­tar­ söz­cük­ler: Özofagus kanseri, nitrik oksit, prolidaz, total 
antioksidan kapasitesi, total oksidan durumu.
ABSTRACT
Background:­This study aims to assess the prolidase activity, 
nitric oxide levels, and oxidative status in patients with esophageal 
squamous cell carcinoma.
Methods: The study included 30 patients with esophageal 
squamous cell carcinoma (11 males, 19 females; 
mean age 61±3 years; range, 28 to 77 years) and 30 healthy 
controls (10 males, 20 females; mean age 58±5 years; 
range, 31 to 73 years). Serum prolidase activity, total antioxidant 
capacity, total oxidant status, and nitric oxide levels were 
measured. In addition, the oxidative stress index was calculated.
Results:­Prominently elevated serum prolidase activity, oxidative 
stress index values, total oxidant status, and nitric oxide levels 
were detected in the patient group (p<0.05). Lower total 
antioxidant capacity levels were observed in the patient group 
(p<0.05).
Conclusion:­ Increased oxidant status with increased nitric 
oxide levels and prolidase activity were found in esophageal 
squamous cell carcinoma patients. Impairment of antioxidant 
mechanism with increased prolidase activity and nitric oxide 
levels may have a crucial role in the etiopathogenesis of 
esophageal squamous cell carcinoma.
Keywords: Esophageal cancer, nitric oxide, prolidase, total antioxidant 
capacity, total oxidant status.
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Esophageal squamous cell carcinoma (ESCC) 
is the most commonly detected malignancy type 
of esophagus. This aggressive malignancy is 
characterized with poor prognosis and high metastasis 
rate.[1] The main treatment is surgical resection of 
the esophagus. Chemoradiotherapy can also be an 
alternative or adjuvant therapy. Smoking, drinking 
alcohol, and low fruit and vegetable intake have been 
claimed as risk factors in ESCC.[2] The chemicals in 
cigarette and alcohol may have important roles in the 
development of premalignant and malignant esophagus 
lesions.[2] These chemicals such as nitrosamine and 
acetaldehyde are prooxidants and they lead to generate 
reactive oxygen species and rise of oxidative stress.[3,4] 
Incremented oxidative stress were found to be related 
to the etiopathogenesis of esophagus cancer.[5]
Nitric oxide (NO) is a vasodilator molecule 
that derives from L-arginine. Nitric oxide, a 
neural transmitter, also has muscle relaxant and 
antiaggregant effects. Production of NO increases 
during inflammation. And chronic inflammation 
leads to increased NO synthesis that has a key role in 
carcinogenesis.[6] Nitric oxide leads to angiogenesis, 
inhibition of the apoptosis progression of the tumor, 
invasion, and metastasis in different tumors.[7] 
On the other hand, the inhibitory effect of NO 
on carcinogenesis and progression of tumor was 
reported.[7] The other effect of NO is phosphorylation 
of different proteins. Nitric oxide was demonstrated 
to increase prolidase activity via phosphorylation.[8]
Matrix metalloproteinases (MMPs) have important 
functions in collagen metabolism and remodeling 
of the extracellular matrix. The extracellular 
matrix is one of the important roadblocks for the 
tumor invasion. Activation of the MMPs leads to 
degradation of the extracellular matrix and this 
situation is the key point for tumor invasion and 
metastasis. Prolidase, a MMP, functions for cleaving 
proline and hydroxyproline from imidodipeptides.[9,10] 
Degradation of the collagen is an important pathway 
to obtain proline and hydroxyproline amino acids that 
are essential in other metabolic reactions and energy 
production. Prolidase degrades collagen to provide 
these amino acids.[10] Also, it was mentioned that 
prolidase promoted angiogenic signaling in tumors.[10] 
Many researchers claimed that prolidase activity may 
be related to tumorigenesis and this relationship was 
presented in different studies.[11-13] Thus, increased 
activity of prolidase was demonstrated in different 
malignancies.[11-13]
According to the literature, oxidative stress, NO 
levels, and prolidase activity are important factors 
in the development and spread of tumor. Hence, in 
this study, we aimed to assess the prolidase activity, 
NO levels, and oxidative stress status in patients with 
ESCC.
PATIENTS AND METHODS
This prospective study was conducted at Van 
Yüzüncü Yıl University Faculty of Medicine and 
Sakarya University Faculty of Medicine Thoracic 
Surgery Clinics between March 2013 and March 2017 
and included 30 patients with ESCC (11 males, 
19 females; mean age 61±3 years; range, 28 to 77 years) 
and 30 healthy controls (10 males, 20 females; 
mean age 58±5 years; range, 31 to 73 years). The 
definite diagnosis of ESCC was confirmed after 
investigation of the biopsy/surgery materials by a 
pathologist. Exclusion criteria were consumption 
of antioxidant or vitamin supplements, smoking 
or drinking alcohol. Patients with active infection 
or chronic systemic disorder or those treated with 
radiotherapy or chemotherapy were also excluded. 
The control group included individuals who had 
admitted to hospital for routine check-up. They 
had no symptoms and their clinical examination 
was totally normal. The exclusion criteria for the 
control group were the same as the patient group. 
The study protocol was approved by the Sakarya 
University Faculty of Medicine Ethics Committee. 
A written informed consent was obtained from each 
participant. The study was conducted in accordance 
with the principles of the Declaration of Helsinki.
Blood samples were obtained after an overnight 
fasting and stored at 4°C. To separate the blood 
cells and the serum, the samples were centrifuged 
at 3000 rpm for 10 minutes and stored at -80°C. 
Afterwards, total antioxidant capacity (TAC), total 
oxidant status (TOS), prolidase activity, and NO 
levels were measured. Blood samples were taken from 
all patients before surgical treatment.
Serum TAC was counted by using an automatic 
method that was described by Erel.[14] The results 
were considered as mM Trolox equivalent per liter. 
Serum TOS was counted by using an automatic 
method that was described by Erel.[15] The oxidative 
stress index (OSI) was found by dividing the TOS 
level by the TAC level. The activity of prolidase 
was determined according to the Myara method and 
the results were considered as U/L.[16] The levels of 
NO were measured by using the Griess reaction, 
according to the method described by Tracey.[17] The 
results were considered as µmol/L.
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Statistical analysis
The statistical evaluation was performed by using 
the SPSS version 16.0 software (SPSS Inc., Chicago, 
IL, USA). The means and standard deviations of 
the results were determined. Normality of the 
distribution was determined with Shapiro-Wilk test. 
The changes between the groups were evaluated 
with Mann-Whitney U test for non-parametric 
factors and with Student’s t-test for parametric 
factors. P values lower than 0.05 were accepted as 
statistically significant.
RESULTS
The demographic characteristics of study 
participants were demonstrated in Table 1. No distinct 
differences were observed between the patient and 
control groups with respect to age, gender, or body 
mass index (p>0.05).
All patients underwent surgical treatment while 
16 patients were also treated with chemotherapy and/or 
radiotherapy. Grade 1 tumor was demonstrated in eight 
patients, grade 2 tumor in 12 patients, and grade 3 
tumor in 10 patients. Submucosal tumor was observed 
in five patients, muscularis propria invasion in eight 
patients, and adventitia invasion in 17 patients. Lymph 
node metastasis was detected in 14 patients. There 
were three upper esophagus, 16 middle esophagus, 
and 11 lower esophagus tumors. Fourteen cases were 
in stage I+IIA, six cases were in stage IIB, and seven 
cases were in stage III. Three cases were inoperable 
because of aortic invasion (stage IV). 
Prominently elevated prolidase activity, TOS levels, 
OSI values, and NO levels were observed in the 
patient group compared to the control group (p<0.05), 
whereas the TAC levels were found to be statistically 
significantly lower in the patient group than the control 
group (p<0.05) (Table 2).
Statistically significantly higher prolidase 
activity, TOS levels, OSI values, and NO levels were 
demonstrated in advanced stage patients compared to 
early stage patients (p<0.05) while TAC levels were 
decreased in advanced stage patients (p<0.05).
DISCUSSION
In this research, we found increased NO levels, 
prolidase activity, and TAC levels in patients with 
esophageal squamous cell carcinoma, while TOS levels 
were lower. Moreover, NO levels, prolidase activity, 
and TAC levels were found to be elevated in advanced 
stage patients compared to early stage patients.
Table 1. Demographic characteristics of study participants
Patients (n=30) Controls (n=30)
Parameters n Mean±SD n Mean±SD p









Body mass index (kg/m2) 22.1±1.6 23.0±1.1 NS
SD: Standard deviation; NS: Non-significant.
Table 2. Prolidase activity, nitric oxide, and oxidant/antioxidant levels in esophageal 
squamous cell carcinoma patients and controls
Patients (n=30) Controls (n=30)
Parameters Mean±SD Mean±SD p
TAC (mmol trolox equiv./L) 4.2±0.0 9.7±0.6 0.05
TOS (µmol H2O2 equiv./L) 20.2±4.4 8.6±2.5 0.05
OSI (arbitrary unit) 4.9±1.1  0.9±0.2 0.05
NO (µmol/L) 20.5±3.9 9.7±0.3 0.05
Prolidase (U/L) 44.9±4.6 24.2±3.5 0.05
SD: Standard deviation; TAC: Total antioxidant capacity; mmol Trolox Equiv./L: mM Trolox equivalent per liter; TOS: Total 
oxidant status; H2O2: Hydrogen peroxide; OSI: Oxidative stress index; NO: Nitric oxide.
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We are exposed to many endogenous and exogenous 
stressors during the day. Oxidative stress leads to 
formation of free oxygen radicals. These radicals 
play role in deoxyribonucleic acid (DNA) damage 
which is important in cell cycle. Extracellular and 
intracellular antioxidant mechanisms are important to 
prevent the harmful effects of oxidant stress. Ensuring 
body’s oxidant-antioxidant balance is essential for the 
continuing of homeostasis. Imbalance in oxidative 
stress may lead to increased DNA damage. Mutations 
related to DNA damage may be an initial factor in 
carcinogenesis.[18] Oxidative stress has been accepted 
as a predisposing factor in the development of many 
cancers.[18] Furthermore, the relationship between 
different malignancies with TOS and TAC levels 
was investigated in a great number of studies.[19-21] 
TOS and OSI index were found higher in esophageal 
cancer patients compared to controls.[21] Moreover, 
these biomarkers were reported to be candidates in 
the diagnosis of esophageal cancer.[21] On the other 
hand, authors demonstrated no correlation between 
stage of cancer and TOS levels.[21] This correlation 
was shown in breast cancer patients; the TOS and the 
TAC levels were presented as prognostic biomarkers 
in breast cancer.[19] In the current research, we found 
a correlation between stage and oxidative stress status 
in contrast with the other study related to esophageal 
cancer. This difference may be related to the different 
geographical and personal characteristics of the 
patients in the study groups.
Deteriorated antioxidant enzyme systems 
have been reported to be associated with cancer 
development. Low levels of antioxidants can activate 
tumor cells as well as elevate lipid peroxides in 
the body.[22] A study reported beneficial effects of 
antioxidant supplementation in the control of cancer 
development.[23] Another study demonstrated that a 
diet rich in fruits and vegetables may reduce oxidative 
stress and cancer risk.[24]
Collagen and extracellular matrix proteins are 
important in the maintenance of cell interaction and 
cell differentiation. Also, they have a significant 
function in tissue stabilization and preventing tumoral 
invasion. Matrix metalloproteinases have key roles 
in the spread of tumor by degrading collagen and 
extracellular matrix components.[25] Prolidase, a MMP 
family member, has functions in collagen turnover and 
remodeling of the matrix.[16] Distortion in collagen 
metabolism was demonstrated in stomach cancer tissue 
while higher prolidase activity was detected in tumoral 
tissue.[26] The importance of prolidase activity was 
investigated in several studies and increased activity 
was demonstrated in different cancer types.[11-13,27] 
Additionally, a positive correlation was detected 
between tumor volume and prolidase activity in gastric 
cancer patients.[11] A study related to breast cancer 
revealed that stage of the disease and tumor size were 
correlated with prolidase activity.[12] It was claimed 
that anti-prolidase activity agents may be crucial in 
the treatment of breast cancer.[27] We found higher 
serum prolidase activity in ESCC patients compared to 
healthy controls. Also, there was a positive correlation 
between stage of ESCC and prolidase activity. To our 
knowledge, this is the first study that investigated 
prolidase activity in ESCC patients.
Nitric oxide is known as a vasodilator molecule; 
however, it also enhances collagen metabolism by 
stimulating prolidase activity. It was reported that 
NO led to phosphorylation of the prolidase and 
phosphorylated prolidase was more active in collagen 
metabolism.[8] Angiogenic and proliferative effect of 
NO on tumor cells were demonstrated.[7] These effects 
are crucial in the spread of tumor. On the contrary, 
another report mentioned that NO had antitumor 
and antiproliferative effects.[28] A study on colon 
cancer showed that NO has an important role in the 
development of cancer, tumor invasion, and spread of 
the tumor.[29] Furthermore, NO were presented as an 
important factor in the development of gastrointestinal 
system tumors.[30] In an experimental study, foods 
that inhibit NO production were found useful in 
the prevention of the occurrence of esophageal 
tumor.[31] Many studies have presented higher NO 
levels in different malignancies such as head and 
neck, bladder, and gynecological cancers.[32-34] In the 
current research, elevated NO levels were detected in 
ESCC patients with respect to control subjects. In a 
study of Prestidge et al.,[35] NO levels in patients with 
esophageal cancer were significantly different than 
the control group and this situation played a role in 
the progression of esophageal cancer. Plasma NO 
levels might be used as biomarkers for the diagnosis 
of esophageal cancer.
This prospective study has some limitations. The 
sample size was limited because of the exclusion criteria 
related to smoking and drinking alcohol. Moreover, we 
did not measure NO or prolidase biomarkers in the 
tumoral tissue. Studies with larger sample sizes may 
provide further valuable information regarding these 
biomarkers in ESCC patients.
In conclusion, we investigated the prognostic 
significance of total oxidant status, oxidative stress 
index, total antioxidant capacity, nitric oxide levels, 
and prolidase activity in esophageal squamous cell 
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carcinoma patients. Increased prolidase activity, nitric 
oxide, total oxidant status, and oxidative stress index 
levels were detected in esophageal squamous cell 
carcinoma patients with decreased total antioxidant 
capacity levels. In addition, these values were correlated 
with the stage of the disease.
Declaration of conflicting interests
The authors declared no conflicts of interest with respect to 
the authorship and/or publication of this article.
Funding
The authors received no financial support for the research 
and/or authorship of this article.
REFERENCES
1.  Kuwano H, Nakajima M, Miyazaki T, Kato H. Distinctive 
clinicopathological characteristics in esophageal squamous 
cell carcinoma. Ann Thorac Cardiovasc Surg 2003;9:6-13.
2.  Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, 
Lagergren P, et al. Oesophageal cancer. Nat Rev Dis Primers 
2017;3:17048. 
3.  Chow CK. Cigarette smoking and oxidative damage in the 
lung. Ann N Y Acad Sci. 1993;686:289-98.
4.  Morita M, Kumashiro R, Kubo N, Nakashima Y, Yoshida 
R, Yoshinaga K, et al. Alcohol drinking, cigarette smoking, 
and the development of squamous cell carcinoma of the 
esophagus: epidemiology, clinical findings, and prevention. 
Int J Clin Oncol 2010;15:126-34.
5.  Kubo N, Morita M, Nakashima Y, Kitao H, Egashira A, Saeki 
H, et al. Oxidative DNA damage in human esophageal cancer: 
clinicopathological analysis of 8-hydroxydeoxyguanosine 
and its repair enzyme. Dis Esophagus 2014;27:285-93.
6.  Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide 
in tumour progression. Nat Rev Cancer 2006;6:521-34.
7.  Choudhari SK, Chaudhary M, Bagde S, Gadbail AR, Joshi 
V. Nitric oxide and cancer: a review. World J Surg Oncol 
2013;11:118.
8.  Surazynski A, Liu Y, Miltyk W, Phang JM. Nitric 
oxide regulates prolidase activity by serine/threonine 
phosphorylation. J Cell Biochem 2005;96:1086-94.
9.  Aslan M, Duzenli U, Esen R, Soyoral YU. Serum prolidase 
enzyme activity in obese subjects and its relationship with 
oxidative stress markers. Clin Chim Acta 2017;473:186-90. 
10.  Surazynski A, Donald SP, Cooper SK, Whiteside MA, Salnikow 
K, Liu Y, et al. Extracellular matrix and HIF-1 signaling: the 
role of prolidase. Int J Cancer. 2008;122:1435-40.
11.  Celik S, Kızıltan R, Yılmaz EM, Yılmaz Ö, Demir H. Potential 
diagnostic and prognostic significance of plasma prolidase 
activity in gastric cancer. Biomark Med 2017;11:319-27.
12.  Bayhan Z, Zeren S, Kocak C, Kocak FE, Duzgun SA, Algin 
MC, et al. Prolidase activity and oxidative stress in patients 
with breast carcinoma A prospective randomized case-
controlled study. Ann Ital Chir 2016;87:517-24.
13.  Camuzcuoglu H, Arioz DT, Toy H, Kurt S, Celik H, Aksoy 
N. Assessment of preoperative serum prolidase activity in 
epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 
2009;147:97-100.
14.  Erel O. A novel automated direct measurement method for 
total antioxidant capacity using a new generation, more stable 
ABTS radical cation. Clin Biochem 2004;37:277-85.
15.  Erel O. A new automated colorimetric method for measuring 
total oxidant status. Clin Biochem 2005;38:1103-11. 
16.  Myara I, Stalder JF. Plasma prolidase and prolinase activity 
in prolidase deficiency. Clin Chem 1986;32:562.
17.  Tracey WR, Tse J, Carter G. Lipopolysaccharide-induced 
changes in plasma nitrite and nitrate concentrations 
in rats and mice: pharmacological evaluation of nitric 
oxide synthase inhibitors. J Pharmacol Exp Ther 
1995;272:1011-5.
18.  Sosa V, Moliné T, Somoza R, Paciucci R, Kondoh H, 
LLeonart ME. Oxidative stress and cancer: an overview. 
Ageing Res Rev 2013;12:376-90.
19.  Feng JF, Lu L, Zeng P, Yang YH, Luo J, Yang YW, et al. 
Serum total oxidant/antioxidant status and trace element levels 
in breast cancer patients. Int J Clin Oncol 2012;17:575-83.
20.  Wang D, Feng JF, Zeng P, Yang YH, Luo J, Yang YW. Total 
oxidant/antioxidant status in sera of patients with thyroid 
cancers. Endocr Relat Cancer 2011;18:773-82.
21.  Huang Q, Feng J, Wu R, Yang Y, Dai C, Li J, et al. 
Total Oxidant/Antioxidant Status in Sera of Patients with 
Esophageal Cancer. Med Sci Monit 2017;23:3789-94.
22.  Sharma A, Rajappa M, Saxena A, Sharma M. Antioxidant 
status in advanced cervical cancer patients undergoing 
neoadjuvant chemoradiation. Br J Biomed Sci 2007;64:23-7.
23.  Borek C. Dietary antioxidants and human cancer. Integr 
Cancer Ther 2004;3:333-41.
24.  Halliwell B. Effect of diet on cancer development: is 
oxidative DNA damage a biomarker? Free Radic Biol Med 
2002;32:968-74.
25.  Yoon SO, Park SJ, Yun CH, Chung AS. Roles of matrix 
metalloproteinases in tumor metastasis and angiogenesis. J 
Biochem Mol Biol 2003;36:128-37.
26.  Guszczyn T, Sobolewski K. Deregulation of collagen 
metabolism in human stomach cancer. Pathobiology 
2004;71:308-13.
27.  Cechowska-Pasko M, Pałka J, Wojtukiewicz MZ. Enhanced 
prolidase activity and decreased collagen content in breast 
cancer tissue. Int J Exp Pathol 2006;87:289-96.
28.  Eijan AM, Davel LE, Rueda HA, Rozenberg G, De Lustig ES, 
Jasnis MA. Differential nitric oxide release and sensitivity to 
injury in different murine mammary tumor cell lines Int J 
Mol Med 1998;2:625-30.
29.  Mandal P. Insight of nitric oxide signaling: A potential 
biomarker with multifaceted complex mechanism in 
colorectal carcinogenesis. Biochem Biophys Res Commun 
2018;495:1766-8.
30.  de Oliveira GA, Cheng RYS, Ridnour LA, Basudhar D, 
Somasundaram V, McVicar DW, et al. Inducible Nitric Oxide 
Synthase in the Carcinogenesis of Gastrointestinal Cancers. 
Antioxid Redox Signal 2017;26:1059-77.
31.  Stoner GD, Wang LS. Chemoprevention of esophageal 




Serum prolidase activity, total oxidant/antioxidant, and nitric oxide levels in patients with esophageal squamous cell carcinoma
32.  Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, 
Vergari WA, et al. Role of nitric oxide in angiogenesis and 
tumor progression in head and neck cancer. J Natl Cancer 
Inst 1998;90:587-96.
33.  Eiján AM, Piccardo I, Riveros MD, Sandes EO, Porcella H, 
Jasnis MA, et al. Nitric oxide in patients with transitional 
bladder cancer. J Surg Oncol 2002;81:203-8.
34.  Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-
Moreno V, Moncada S. Nitric oxide synthase activity in human 
gynecological cancer. Cancer Res 1994;54:1352-4.
35.  Prestidge BR, Kaplan I, Cox RS, Bagshaw MA. The 
clinical significance of a positive post-irradiation prostatic 
biopsy without metastases. Int J Radiat Oncol Biol Phys 
1992;24:403-8.
